Sanofi Developing New Drug For Breast Cancer
 

Sanofi Developing New Drug For Breast Cancer

When Sanofi paid 500 million for BiPar Sciences, they had no clue that they were also buying the rights to a potential blockbuster drug.
BiPar Sciences is a company comprised of 18 people, who have been working on an experimental breast <NOBR style="FONT-WEIGHT: bold" id=itxt_nobr_1_0>cancerhttp://images.intellitxt.com/ast/adT...lass_10x10.gif</NOBR> vaccine with great vigor.
The vaccine is called BSI-201 and in a clinical trial, lengthened survival for women taking it by 6 months.
Sanofi’s chief medical officer Paul Chew, says that the drug could someday be the next leading treatment for women diagnosed with aggressive forms of breast cancer.
BiPar was located in the city of San Francisco and their researchers will stay there and keep working on the new drug.
“These 18 people brought this product to where it is now” and will be able to develop the drug more quickly than if the company took over the process,” said a member of the company.

Sanofi's new CEO is Mr. Chris Viebacher who was formally the President of GSK-United States. Chris was instrumental in bringing Tykerb to market.

We have met him at several patient advocate receptions both at San Antonio and ASCO and are impressed by his compassion to help all cancer patients.

http://www.her2support.org/temp/cs.jpg




Christine, Mr. Viebacher and our precious Sandy H. at SABCS

Regard
Joe